The company's R & D center has 10 professional R & D engineers, including 2 doctoral degrees (Dr. Yu Hao Yang for the Peacock Class B talent in Shenzhen City, the national "thousands of people plan" candidates; Professor Wang Zhong for the Sun Yat-sen University, , Guangdong Province, the introduction of core team of talent), master 3, 4 undergraduate, specialist 1. R & D center is divided into immunotherapy products, antibody products, research and development of quality control.
Yu Hao Yang, general manager of Bentcon Biopharmaceutical (Shenzhen) Co., Ltd. German biology doctor, Shenzhen City, "Peacock Plan" talent, visiting professor of Shenzhen University, Shenzhen Jin Baihui Biological Co., Ltd. General Manager. He was the project manager at R & D and Quality and Safety Headquarters, a health care company in Bayer Pharmaceuticals, the world's top 500 companies. Dr. Yu Haoyang belongs to the Shenzhen Municipal People's Government in 2011 to introduce overseas high-level innovative talents, mainly engaged in gastrointestinal digestive diseases in the basic theory of research, as the German Association of Gastrointestinal and Metabolic Diseases in the digestive system cell membrane protein and ion Access to the research done a lot of work, published many articles SCI, apply for invention patents 6.
Wang Zhong, Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. technical adviser. Professor, doctoral tutor, hundred people plan. 2002 Ph.D. in Biochemistry and Molecular Biology, School of Medicine, Indiana University. 2002 - 2010 in the United States Stanford University School of Medicine to do postdoctoral research, and then served as research assistant and lecturer. After that, Amgen in the United States to develop various types of drugs. At the end of 2012 to teach Sun Yat-sen University School of Pharmacy. Guangdong Province is the third batch of innovative scientific research team to introduce the core members. Mainly engaged in drug design and development, biological drug design application research. By designing and developing different macromolecules (monoclonal antibodies, fusion proteins, etc.) to stimulate the immune system to attack tumor cells in order to achieve the treatment of cancer, as well as other major diseases prevention and treatment. In recent years published many SCI papers, including the international top magazine "natural" "cancer cells" and so on.
Li Zhengcheng, R & D center manager, R & D engineer. Master of cell biology, mainly engaged in tumor immunotherapy related research, technology transformation and promotion. Nearly two years published two related articles, apply for national invention patent 3, PCT patent 2 items.
He Chengsi, R & D Engineer. Graduated from Shenzhen University biotechnology professional, after graduation mainly engaged in the field of immune cell therapy work. Incumbent Biology Pharmaceutical (Shenzhen) Co., Ltd. R & D personnel. Mainly engaged in research and development work, animal experiments and experimental platform for daily work management.
Ma Peng, R & D engineers. Master of Biomedical Engineering. Mainly engaged in biological agents, materials research and development work.
Deng Wen copper, R & D engineers. Master of Microbiology and Biopharmaceutics. Mainly engaged in antibody product development work.